43 related articles for article (PubMed ID: 11546782)
21. Biotransformation of the chemopreventive agent 2',4',4-trihydroxychalcone (isoliquiritigenin) by UDP-glucuronosyltransferases.
Guo J; Liu A; Cao H; Luo Y; Pezzuto JM; van Breemen RB
Drug Metab Dispos; 2008 Oct; 36(10):2104-12. PubMed ID: 18653743
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.
Miley MJ; Zielinska AK; Keenan JE; Bratton SM; Radominska-Pandya A; Redinbo MR
J Mol Biol; 2007 Jun; 369(2):498-511. PubMed ID: 17442341
[TBL] [Abstract][Full Text] [Related]
23. Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family.
Kobayashi T; Sleeman JE; Coughtrie MW; Burchell B
Biochem J; 2006 Dec; 400(2):281-9. PubMed ID: 16965264
[TBL] [Abstract][Full Text] [Related]
24. cDNA cloning and functional analysis of minipig uridine diphosphate-glucuronosyltransferase 1A1.
Miyake Y; Mayumi K; Jinno H; Tanaka-Kagawa T; Narimatsu S; Hanioka N
Biol Pharm Bull; 2013; 36(3):452-61. PubMed ID: 23449330
[TBL] [Abstract][Full Text] [Related]
25. Role of cysteine residues in the function of human UDP glucuronosyltransferase isoform 1A1 (UGT1A1).
Ghosh SS; Lu Y; Lee SW; Wang X; Guha C; Roy-Chowdhury J; Roy-Chowdhury N
Biochem J; 2005 Dec; 392(Pt 3):685-92. PubMed ID: 16171463
[TBL] [Abstract][Full Text] [Related]
26. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome.
Thummala NR; Ghosh SS; Lee SW; Reddy B; Davidson A; Horwitz MS; Chowdhury JR; Chowdhury NR
Gene Ther; 2002 Aug; 9(15):981-90. PubMed ID: 12101428
[TBL] [Abstract][Full Text] [Related]
27. Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1.
Apgar JF; Tang JP; Singh P; Balasubramanian N; Burke J; Hodges MR; Lasaro MA; Lin L; Millard BL; Moore K; Jun LS; Sobolov S; Wilkins AK; Gao X
CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):404-412. PubMed ID: 29637732
[TBL] [Abstract][Full Text] [Related]
28. Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications.
Ghosh SS; Sappal BS; Kalpana GV; Lee SW; Chowdhury JR; Chowdhury NR
J Biol Chem; 2001 Nov; 276(45):42108-15. PubMed ID: 11546782
[TBL] [Abstract][Full Text] [Related]
29. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.
Kadakol A; Ghosh SS; Sappal BS; Sharma G; Chowdhury JR; Chowdhury NR
Hum Mutat; 2000 Oct; 16(4):297-306. PubMed ID: 11013440
[TBL] [Abstract][Full Text] [Related]
30. [Genetic defect of the hyperbilirubinemic Gunn rat, a model for Crigler-Najjar syndrome type I].
Sato H; Aono S; Koiwai O
Nihon Rinsho; 1993 Feb; 51(2):501-6. PubMed ID: 8096554
[TBL] [Abstract][Full Text] [Related]
31. [Gilbert disease and type I and II Crigler-Najjar syndrome due to mutations in the same UGT1A1 gene locus].
Kraemer D; Scheurlen M
Med Klin (Munich); 2002 Sep; 97(9):528-32. PubMed ID: 12371080
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
